Comparison
Testosterone & TRT vs. Enclomiphene
Testosterone therapy or enclomiphene – what is the difference?
The short answer
Both raise the testosterone level, but by opposite routes – and that decides fertility. Testosterone therapy supplies the hormone from outside and thereby suppresses the body’s own production, including sperm production. Enclomiphene blocks the feedback at the pituitary gland and lets the body produce more itself; spermatogenesis is preserved. The data on hormone levels are good: two phase 3 trials with 256 men show testosterone levels of 430 to 445 ng/dl after 16 weeks versus 214 to 236 ng/dl under placebo, with sperm production preserved. Only two of ten studies assessed symptoms, and safety data extend over only 16 weeks. The catch: testosterone is approved, enclomiphene is approved nowhere. The US marketing application was rejected at the end of 2015 – on the grounds of the trial design, not of cardiovascular safety data.
The numbers side by side
| Axis | Testosterone & TRT | Enclomiphene | Difference |
|---|---|---|---|
| Human evidenceHow much and how good the data in humans are | 9 | 7 | Testosterone & TRT better studied |
| MechanismHow well the chain of action is understood | 9 | 9 | even |
| Safety dataHow well safety has been studied – not how safe it is | 9 | 4 | Testosterone & TRT better studied |
| Hype gap10 means: the advertising stays level with the data | 4 | 5 | Enclomiphene closer to the data |
| Track record of useHow much documented use in humans exists – does not measure whether it works | 10 | 4 | Testosterone & TRT in use longer |
| Rating | Well supported, heavily overhyped · Supported, with caveats | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules (German). It is not a scientific rating, not the consensus of a professional society and not a medical recommendation.
Why these numbers
Testosterone & TRT
Replacement therapy for diagnosed hypogonadism has been approved for decades, and the chain of action is established beyond doubt in humans – the question is who gets treated. The TRAVERSE trial (Lincoff et al., NEJM 2023) randomized 5,246 men, treated for a mean of 21.7 months and followed for 33 months: non-inferior on cardiovascular outcomes, but more atrial fibrillation (91 versus 63 cases) and more acute kidney injury. In 2025, the BfArM pointed to the sharply rising number of prescriptions, some of which are issued outside the approved indication. For men with low-normal levels and no diagnosis, there is no approval trial.
Enclomiphene
Evidence 7: two parallel, randomized, double-blind phase 3 trials with 256 men over 16 weeks and a review of 10 RCTs with 819 men – but exclusively surrogate endpoints, GRADE moderate because of wide confidence intervals and high heterogeneity. Mechanism 9: the chain of action has been quantified throughout in humans – LH and FSH rise with p below 0.001, testosterone after 16 weeks 430 to 445 ng/dl versus 214 to 236 ng/dl under placebo, sperm concentration plus 11 to 15 percent instead of minus 33 to 57 percent under gel. Safety 4: only short-term data – 16 weeks in 256 men, the review itself calls its safety analysis underpowered; for comparison, TRAVERSE followed 5,246 men over about 33 months. Hype 5: the advertised mechanism is correct and the fertility advantage is real, but the portrayal as an approval-ready and safer TRT alternative is doubly overstretched – for the testosterone level, the difference from the gel is 5.4 ng/dl (p = 0.83), and the substance is not approved anywhere. Use 4: widespread via compounding and the gray market, without a regulatory framework. Direction positive: the available data support the claimed effects on testosterone, LH, FSH and sperm preservation; they do not speak against them. What remains open – not refuted – is the clinical benefit, since only 2 of 10 studies assessed symptoms. The rejection came on December 1, 2015 and was justified by the trial design, not by cardiovascular safety data; the review pools clomiphene and enclomiphene together.
Frequently asked questions
Does testosterone therapy make you infertile?
It suppresses the body’s own production and with it sperm production – reversibly after stopping in most men, but not in all and not quickly. That is why hCG is often added in practice to preserve testicular function; this combination is off-label and not supported by approval trials of its own.
What did the TRAVERSE trial show?
It randomized 5,246 men with cardiovascular risk, treated for a mean of 21.7 months and followed for 33 months. Testosterone was non-inferior to placebo for major cardiovascular events – but there were more cases of atrial fibrillation and acute kidney injury.
Is enclomiphene available in Germany?
Not as an approved finished medicinal product. Only the racemate clomiphene is approved, specifically for women; use in men is off-label.
See all 255 ratings in the ranking (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in a doctor's hands.